Delinia is a biotechnology company developing novel therapeutics for the treatment of autoimmune diseases. Delinia’s lead program is a molecule that potentiates and expands Regulatory T Cells (Tregs), powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis. Tregs are critically important immune regulatory cells in the pathophysiology of cancer and autoimmune disease.
Delinia was acquired by Celgene Corporation.
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 14.09.2016 | Series A | $35M | - | finsmes.co... |
Mentions in press and media 5
